Wall Street closes at a record for the first time since end of January
CHICAGO - Tempus AI, Inc. (NASDAQ:TEM) announced a commercial partnership with Predicta Biosciences to expand availability of a co-branded whole-genome sequencing assay for hematologic malignancies, according to a press release statement. The $8.88 billion market cap company has demonstrated strong commercial momentum with revenue growth of 83% over the last twelve months, though it remains unprofitable with a loss of $1.41 per share.
The assay, called GenoPredicta, combines flow cytometry with whole-genome sequencing to analyze cancer genomes from peripheral blood or bone marrow samples. The test can identify genetic alterations from as few as 50 tumor cells, representing a sensitivity of one in a million cells, the companies said.
GenoPredicta is currently available to Tempus Life Sciences partners for research and clinical development programs. The assay has been clinically validated in Multiple Myeloma and other plasma cell dyscrasias and is available for research use only across other indications.
The technology was developed based on research by Predicta scientific co-founder Dr. Irene Ghobrial. The assay identifies genetic alterations including single nucleotide variants, insertions and deletions, copy number variations, and structural variations to support diagnosis, risk classification, and identification of therapy resistance mechanisms.
"By joining forces with Tempus, we are delivering unprecedented sensitivity and clarity to researchers," said Brian McKernan, CEO of Predicta Biosciences.
Kate Sasser, Chief Scientific Officer at Tempus, said the assay consolidates flow cytometry, cytogenetics, and whole-genome sequencing into one workflow. The companies stated the assay delivers concordance between peripheral blood and bone marrow samples.
Tempus operates a data library and provides AI-enabled precision medicine solutions to physicians. Predicta Biosciences develops diagnostic solutions for molecular characterization of hematologic malignancies with a focus on circulating tumor cells.
In other recent news, Tempus AI has announced several significant developments. The company reported an expanded multi-year collaboration with Gilead Sciences, granting Gilead access to Tempus’ AI-driven Lens platform to advance its oncology pipeline. Additionally, Tempus AI has entered into a similar collaboration with Merck, focusing on the discovery and development of precision medicine biomarkers. The ALERT trial results were also unveiled, showing that Tempus AI’s automated electronic clinician notifications significantly improved the evaluation and treatment of heart valve conditions.
In terms of analyst activity, TD Cowen upgraded Tempus AI to a Buy rating, citing stronger company fundamentals despite a previous decline in stock value. The firm set a new price target of $65.00. Meanwhile, Jefferies initiated coverage on Tempus AI with an Underperform rating, highlighting an unclear catalyst path in therapy selection compared to peers. H.C. Wainwright maintained a Buy rating on Tempus AI and raised its price target to $95, reflecting optimism about the company’s recent partnerships. These developments underscore Tempus AI’s ongoing efforts to leverage its AI capabilities in the healthcare sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.